Kolon’s Osteoarthritis Gene Therapy First To Move To U.S. Phase III
This article was originally published in PharmAsia News
Executive Summary
Invossa , a cell-mediated gene therapy for knee osteoarthritis being developed by South Korea's Kolon Group, is set to begin a Phase III clinical trial in the U.S. after receiving approval from the FDA earlier this month, and appears to be the first such therapy for the indication to progress this far.